ReviewOphthalmology and therapy2022
A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications.
Review in Ophthalmology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- A phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension.Eye (London, England) · 2025Trial
- Fifteen-Month Outcomes of Preservative-Free Latanoprost Cationic Emulsion in Open-Angle Glaucoma and Ocular Hypertension: Phase III Open-Label Extension of a Randomized Trial.Clinical ophthalmology (Auckland, N.Z.) · 2025Trial
- Phase 3, Randomized Study Comparing Intracameral Bimatoprost Implant 15 µg and Selective Laser Trabeculectomy in Patients with Open-Angle Glaucoma or Ocular Hypertension.Clinical ophthalmology (Auckland, N.Z.) · 2023Trial
- Association of Comprehensive Geriatric Assessment with Knowledge- and Technique-Related Eye Drop Adherence Problems in Glaucoma Assessed Using the Shimane University Glaucoma Eye Drop Adherence Questionnaire.Journal of clinical medicine · 2026Article
- Unseen Consequences: The Expanding Burden of Iatrogenic Dry Eye Disease in Surgical and Cosmetic Practice.Turkish journal of ophthalmology · 2026Review
- The Effects of Intraocular Pressure-Lowering Drops on the Tear Film Assessed by a Novel High-Resolution Tear Film Imager.Diagnostics (Basel, Switzerland) · 2026Article
- Comparative Effectiveness of Timolol-Based Fixed-Combination Regimens for Glaucoma: a Retrospective Cohort Study Using Target Trial Emulation Framework.Ophthalmology and therapy · 2026Article
- Digoxin Attenuates Ocular Hypertension and Protects Trabecular Meshwork Cells via Ferroptosis Inhibition.Investigative ophthalmology & visual science · 2026Article
- Optimizing Ocular Surface Disease (OSD) Management in Patients with Glaucoma: Expert Strategies from Asia.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Ocular Surface Changes and Glaucoma: A Prospective Contralateral Study of IOP-Reducing Eyedrops versus iStent Inject Surgery.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Quality of life in medically & surgically treated patients with glaucoma.The Indian journal of medical research · 2025Observational
- Potential benefits of vitamin A and its derivatives in glaucoma.European journal of medical research · 2025Review
- Impact of Antiglaucoma Drug Number and Class on Corneal Epithelial Thickness Measured by OCT.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Unraveling the effects of serial intravitreal Aflibercept injections on the ocular surface of patients with glaucoma and retinal comorbidity.Scientific reports · 2025Observational
- Bibliometric and visualized analysis of research hotpots and future prospects in lacrimal duct obstruction disease (1900 to 2024).International journal of ophthalmology · 2025Article
- Managing Ocular Surface Disease in Glaucoma Treatment: A Systematic Review.Bioengineering (Basel, Switzerland) · 2024Review
- Review
- Activation of ADRB2/PKA Signaling Pathway Facilitates Lipid Synthesis in Meibocytes, and Beta-Blocker Glaucoma Drug Impedes PKA-Induced Lipid Synthesis by Inhibiting ADRB2.International journal of molecular sciences · 2022Article
- Objective Evaluation of Ocular Surface Adverse Effects in Patients Receiving Topical Antiglaucoma Treatment.Romanian journal of ophthalmologyArticle
- Short-term effects of antiglaucomatous topical medication on the ocular surface in Wistar rats.Romanian journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Topical anti-glaucomatous medications are still the most important measure to lower intraocular pressure. Large number of studies have confirmed that long-term use of anti-glaucomatous eye drops, especially containing benzalkonium chloride, a preservative, can cause or aggravate ocular surface injury. Ocular surface diseases damage the ocular microenvironmental health status, reduce the patients' compliance with the treatment, and finally affect the treatment result. Therefore, the ocular surface management of patients with glaucoma is very important. This includes the selection of drugs that are better tolerated according to individual conditions, preservative-free formulations, drugs that protect against ocular surface disease, or selecting surgery and laser treatment, to prevent the damage to the ocular surface by topical anti-glaucomatous drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.